Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Go-Gold, TheHungryHippo, BluSkies, GoldenMind, Rdy1
Search This Board: 
Last Post: 9/26/2017 8:35:57 AM - Followers: 805 - Board type: Free - Posts Today: 8


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks


Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Current Report Filing (8-k) 09/13/2017 09:01:32 AM
USRM News: Initial Statement of Beneficial Ownership (3) 09/01/2017 04:06:18 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:04:29 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/01/2017 04:02:44 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 08/25/2017 04:07:27 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#79194  Sticky Note SO TO RECAP: COMPANY ON THE CUTTING EDGE OF docprep 09/11/17 02:12:05 PM
#78232  Sticky Note Official response to FDA Warning Letter. Deal McMogulson 08/29/17 02:42:32 PM
#75686  Sticky Note US STEM CELL UPDATE 8/8/2017 8:14:40 pm Eastern GoldenMind 08/08/17 08:14:43 PM
#72621  Sticky Note MYOCELL CLINICAL TRIALS, SIX PATIENT DEATHS !! Hornet Driver 06/29/17 10:22:27 AM
#79949   Lol look at MAXM ask 8dollars for 100 VenOmousInvestor 09/26/17 08:35:57 AM
#79948   Sometime between now and dec 13th I believe. MyzStreet 09/26/17 08:02:01 AM
#79947   USRM Bidding 0.015 BoilerRoom 09/26/17 07:54:19 AM
#79946   Morning give us something!!!!! Let's getting moving already !!!!!! Moke31 09/26/17 07:39:44 AM
#79945   Watch out Hornet, here they come. Eldeano57 09/26/17 07:29:49 AM
#79944   Correct me if I'm wrong...Isnt the FDA new VenOmousInvestor 09/26/17 05:40:55 AM
#79943   Interesting development GeeForceJunkie 09/26/17 12:38:00 AM
#79942   Man that's nothing ! Shouldn't stress at all Cdizz123 09/26/17 12:17:03 AM
#79939   Exactly, I guess the first good news would CanItBThisEZ2Make 09/25/17 10:41:48 PM
#79938   We've had more than a whiff of good docprep 09/25/17 10:32:49 PM
#79937   Agreed! Great post! $USRM MyzStreet 09/25/17 10:15:56 PM
#79936   Wow, I'm too lazy to search something good CanItBThisEZ2Make 09/25/17 10:13:09 PM
#79935   Not selling and not buying it. emit 09/25/17 10:01:54 PM
#79934   This company needs a billionaire to step in emit 09/25/17 09:59:02 PM
#79932   To each thier own. Some invest $1k others GoldenMind 09/25/17 09:54:19 PM
#79931   Stuck with a grand....oh boy....then i need to MOCKBA 09/25/17 09:48:40 PM
#79929   1grand Average .05-6 emit 09/25/17 08:49:49 PM
#79928   How much did you put in this ? Cdizz123 09/25/17 08:47:42 PM
#79927   I hate berating a company I own, but emit 09/25/17 08:46:20 PM
#79926   USRM Don't care what anyone else does. DeliverySuccess 09/25/17 08:43:23 PM
#79925   This is like starting at the bottom of moznoz 09/25/17 08:24:25 PM
#79924   He isn't Work Harder 09/25/17 07:36:12 PM
#79923   Wouldn't surprise me. emit 09/25/17 07:21:47 PM
#79922   Sorry for you to think that. GoldenMind 09/25/17 07:06:15 PM
#79918   When the big market is red we are Afterhoursearnings3 09/25/17 05:27:35 PM
#79917   FDA shutdown or some sort of serious punishment coming munimi 09/25/17 05:26:59 PM
#79916   Do they have the time/money to go after emit 09/25/17 05:07:35 PM
#79915   Nothing automated here IMHO. Lonewolf1 09/25/17 04:14:18 PM
#79913   BREAKING! HUGE!!! TruthSpeaker12 09/25/17 03:55:23 PM
#79912   MILLIONS WILL KNOW!!! TruthSpeaker12 09/25/17 03:53:45 PM
#79911   Support at the nine, just as I said TruthSpeaker12 09/25/17 03:51:33 PM
#79910   The Market has been down all day and TruthSpeaker12 09/25/17 03:50:46 PM
#79909 TruthSpeaker12 09/25/17 03:48:54 PM
#79908   GACP TERMINATED $5 mil INVESTMENT AGREEMENT, LOL !!! Hornet Driver 09/25/17 03:47:30 PM
#79907   Wall reduced from 300k to 200k. Sorry but selling docprep 09/25/17 03:33:33 PM
#79906   I'm not sure actually. Mods I think docprep 09/25/17 03:13:21 PM
#79905   Volume is practically non-existent recently. I think Artwalker 09/25/17 03:07:07 PM
#79904   USRM simple buy n hold...chomp chomp... add...add. DeliverySuccess 09/25/17 02:37:40 PM
#79903   Crazy low volume for a Monday. Considering the TruthSpeaker12 09/25/17 02:25:22 PM
#79902   Who chooses what to Sticky? TruthSpeaker12 09/25/17 02:22:19 PM
#79901   We have been working through those daily walls TruthSpeaker12 09/25/17 02:21:21 PM
#79900   300k wall at 2 and 2.1 c Think this docprep 09/25/17 02:02:50 PM
#79899   Sticky this docprep 09/25/17 02:00:09 PM
#79898   looking forward for RMAT application round 2 for GoldenMind 09/25/17 01:39:28 PM
#79897   Couldn't agree more A1! Just a waiting game. Deal McMogulson 09/25/17 01:24:22 PM
#79895   I will say this: the one positive thing a1tellem 09/25/17 12:10:41 PM
#79894   Comella @ RAAD Fest 8-12-2017 MyzStreet 09/25/17 11:21:59 AM
#79893   USRM~NFL Hall of Fame and Long time shareholder MyzStreet 09/25/17 11:17:48 AM
#79892   NO LIQUIDITY CONCERNS Stylus 09/25/17 11:09:46 AM
#79891   So ladies and gentlemen when are those 3's VenOmousInvestor 09/25/17 10:48:29 AM